EKF Diagnostics (LON:EKF) Receives “Buy” Rating from Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of EKF Diagnostics (LON:EKF) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. They currently have a GBX 35 price objective on the stock.

EKF Diagnostics Stock Down 2.6%

Shares of EKF opened at GBX 24.84 on Wednesday. The company has a market capitalization of £107.10 million, a P/E ratio of 52.86 and a beta of 0.49. The company has a debt-to-equity ratio of 2.01, a current ratio of 4.16 and a quick ratio of 1.77. EKF Diagnostics has a one year low of GBX 19 and a one year high of GBX 32. The business’s 50 day simple moving average is GBX 24.91 and its 200-day simple moving average is GBX 25.55.

EKF Diagnostics (LON:EKF) last announced its earnings results on Tuesday, March 24th. The company reported GBX 0.47 EPS for the quarter. EKF Diagnostics had a return on equity of 3.01% and a net margin of 4.12%. As a group, sell-side analysts predict that EKF Diagnostics will post 2.2987842 EPS for the current fiscal year.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.